Ashkan M. Abbey, MD, Presented Real-world Outcomes of Fluocinolone Acetonide Intravitreal Implant for Non-infectious Uveitis at ASRS 2024 Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the
read more
Dr. Abbey Presented Key Results of DAVIO 2 Clinical Trial for Wet AMD at Retina World Congress
At the recently held 2024 Retina World Congress Meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented topline results from the DAVIO 2 clinical trial investigating EYP-1901 (Duravyu),
read more Dr. Abbey Presents GALE Study Data at the Association for Research in Vision and Ophthalmology
At this year’s ARVO 2024, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Texas Retina’s Dr. Abbey presented 36-month data from the GALE study of pegcetacoplan (brand
read more
Dr. Abbey Recognized as a 2023 Top 10 Reviewer for Ophthalmic Surgery Lasers + Imaging Retina Medical Journal
The medical journal Ophthalmic Surgery Lasers + Imaging Retina (OSLI Retina) recently recognized Texas Retina Associates’ Ashkan M. Abbey, MD as a “2023 Top 10 Reviewer” in recognition of the quantity, quality
read more Dr. Abbey Featured as a Panelist in Retina Times Article on Secondary IOL Placement Surgery
In the Winter 2023 issue of Retina Times published by the American Society of Retina Specialists (ASRS), Texas Retina Associates’ Ashkan M. Abbey, MD, was featured in an article titled, “Managing the
read more
Dr. Abbey Taught a Course at the American Academy of Ophthalmology 2023 Annual Meeting
On November 6, Texas Retina Associates’ Ashkan M. Abbey, MD, taught a continuing medical education (CME) course titled, “Secondary IOL Techniques for Retinal Specialists,” at AAO 2023, the annual meeting of the
read more
Three New Clinical Trials Available at Texas Retina
Medical researchers continue to make significant advances in the diagnosis and treatment of retinal conditions, and our physicians remain committed to participating in clinical trials that will improve care for our patients.
read more
New Treatments Available for Geographic Atrophy
We know geographic atrophy (GA) can negatively impact patients’ quality of life and independence. While it still cannot be cured, Texas Retina is excited to finally have two new GA treatment options
read more Dr. Abbey Publishes Case Report on Macular Hole Closure with Intravitreal Dexamethasone Implant
In the September 2023 issue of the peer-reviewed medical journal Ophthalmic Surgery, Lasers and Imaging Retina, Texas Retina’s Ashkan Abbey, MD, describes the use of a dexamethasone intravitreal implant to close a
read more Dr. Abbey Publishes Research on Effectiveness of a Long-acting Injectable Steroid for Patients with Cystoid Macular Edema After Vitrectomy
Long-acting injectable steroids have emerged as a new way to treat chronic intraocular inflammation and cystoid macular edema (CME) that reduces the treatment frequency and burden for retina patients. Texas Retina’s Ashkan
read more